Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality
References
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–93. DOI: 10.1093/eurheartj/ehy136
- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014; 383: 955–62. DOI: 10.1016/S0140-6736(13)62343-0
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. European Journal of Cardio-Thoracic Surgery. 2016; 50: e1–88. DOI: 10.5603/KP.2016.0172
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC
Jr , et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019; 140: e125–51. DOI: 10.1161/CIR.0000000000000719 - Bai Y, Guo S-D, Shantsila A, Lip GYH. Modelling projections for the risks related with atrial fibrillation in East Asia: A focus on ischaemic stroke and death. EP Europace. 2018; 20: 1584–90. DOI: 10.1093/europace/eux328
- Blann AD, Boriani G, Lip GYH. Modelling projections for the uptake of edoxaban in an European population to 2050: Effects on stroke, thromboembolism, and health economics perspectives. Europace. 2016; 18: 1507–13. DOI: 10.1093/europace/euw211
- Karmacharya B, Adeoye A, Di Cesare M, Hakim F, Huffman MD, Katbeh A, et al.
Application for inclusion of non-vitamin K antagonists oral anticoagulant (NOACs) for the treatment of non-valvular atrial fibrillation in the WHO Model List of Essential Medicines 2019 .https://www.who.int/selection_medicines/committees/expert/22/applications/dabigatran/en/2019 . - Yu Z, Yu L, Shan C. Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012–2017. BMC Health Serv Res. 2020; 20: 209. DOI: 10.1186/s12913-020-5072-3
- IMS Institute for Healthcare Informatics. Understanding the Role and Use of Essential Medicines Lists. 2015.
- Neumann I, Schünemann HJ. Application for inclusion of novel oral anticoagulants for the treatment of non-valvular atrial fibrillation in the who model list of essential medicines 2015. 2014.
- 20th Expert Committee on Selection and Use of Essential Medicines. Peer Review Report #2. Novel oral anticoagulants. 2015.
- World Health Organization. Model List of Essential Medicines, 21st List, 2019. 2019.
- Beran D, Yudkin JS, de Courten M. Assessing health systems for type 1 diabetes in sub-Saharan Africa: Developing a “Rapid Assessment Protocol for Insulin Access.” BMC Health Serv Res. 2006; 6: 17. DOI: 10.1186/1472-6963-6-17
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–51. DOI: 10.1056/NEJMoa0905561
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–91. DOI: 10.1056/NEJMoa1009638
- Hori M, Matsumoto M, Tanahashi N, Momomura S-I, Uchiyama S, Goto S, et al. Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation. Circulation Journal. 2012; 76: 2104–11. DOI: 10.1253/circj.CJ-12-0454
- Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981–92. DOI: 10.1056/NEJMoa1107039
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093–104. DOI: 10.1056/NEJMoa1310907
- Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PRE vention o F Thromboembolic Events– E uropean R egistry in A trial F ibrillation). Journal of the American Heart Association. 2017; 6. DOI: 10.1161/JAHA.117.005657
- Kilickap M, Bosch J, Eikelboom JW, Hart RG. Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Can J Cardiol. 2016; 32: 1108–16. DOI: 10.1016/j.cjca.2016.06.003
- Deitelzweig S, Luo X, Gupta K, Mardekian J, Trocio JN, Curtice T, et al. Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion. 2018; 34: 11–2. DOI: 10.1080/03007995.2017.1397989
- Chao T-F, Liu C-J, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, et al. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation. 2018; 138: 37–47. DOI: 10.1161/CIRCULATIONAHA.117.031658
- Liberato NL, Marchetti M. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Review of Pharmacoeconomics & Outcomes Research. 2016; 16: 221–35. DOI: 10.1586/14737167.2016.1147351
- Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019; 380: 1326–35. DOI: 10.1056/NEJMoa1814051
- Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding. Circulation. 2013; 128: 1234–43. DOI: 10.1161/CIRCULATIONAHA.113.002283
- World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. 2013.
- United Nations. Transforming our world: The 2030 Agenda for Sustainable Development. 2015.
DOI: https://doi.org/10.5334/gh.608 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jan 24, 2020
Accepted on: Jun 25, 2020
Published on: Aug 6, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Ezequiel J. Zaidel, Xinyi Leng, Abiodun Moshood Adeoye, Ferdous Hakim, Biraj Karmacharya, Asim Katbeh, Lis Neubeck, Stephanie Partridge, Pablo Perel, Mark D. Huffman, Mariachiara Di Cesare, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.